Neurodegenerative diseases, a heterogeneous group of disorders, are characterized by progressive degeneration of the structure and eventually function of the central and/or peripheral nervous system. The most common neurodegenerative diseases include Alzheimer’s disease and Parkinson’s disease. The prevalence of neurodegenerative disorders in the societies is growing, owing to increasing the number of elderlies. Currently, there is no cure for any of these diseases, and understanding the molecular mechanisms involved in pathophysiology of disease shed light on pharmacological strategies that may be useful for the development of novel drugs for neurodegenerative disease.
Kambiz Hassanzadeh is a neuropharmacologist. He has received his Pharm D degree and then his PhD degree from Tabriz University of Medical Sciences in Iran. Then he joined the laboratory of Professor Sandra Ceccatelli at Karolinska institute of Sweden for 1 year. He went back to Iran and worked in Kurdistan University of Medical Sciences as academic staff. From 2019 he has worked as a senior researcher in Dr. Marco Feligioni lab at European Brain Research Institute (EBRI), Rome. Kambiz research area has focused on the neuropharmacology fields. As his publications illustrates, he has started his research journey on neuroinflammation and pain management during his PhD thesis. Then he was interested to study the neurodegenerative disease specially Parkinson’s disease (PD) and research on role of antioxidant on neurodegeneration. Now he is working on a project focusing on post translational modification (PTM) of α-Synuclein isoforms profile and its impact on α-Synuclein homeostasis and pathophysiology of Parkinson’s disease.